Merck KGaA (OTCMKTS:MKKGY – Get Free Report) shares saw unusually-high trading volume on Monday. Approximately 537,087 shares were traded during trading, an increase of 470% from the average daily volume of 94,300 shares. The stock last traded at $32.88 and had previously closed at $33.07.
Analyst Ratings Changes
MKKGY has been the topic of a number of analyst reports. Zacks Research upgraded shares of Merck KGaA from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 10th. UBS Group lowered shares of Merck KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 20th. Six research analysts have rated the stock with a Hold rating. According to MarketBeat, the company currently has a consensus rating of “Hold”.
Get Our Latest Report on MKKGY
Merck KGaA Stock Down 0.8%
The company has a debt-to-equity ratio of 0.37, a current ratio of 1.69 and a quick ratio of 1.09. The stock has a market capitalization of $21.20 billion, a P/E ratio of 23.94, a PEG ratio of 2.65 and a beta of 0.92. The stock has a 50 day moving average price of $31.74 and a 200-day moving average price of $30.09.
About Merck KGaA
Merck KGaA is a German science and technology company headquartered in Darmstadt. Founded in 1668, it traces its origins to a pharmacy established by the Merck family and has grown into a global business serving customers in healthcare, research and industry. It is separate from the U.S.-based Merck & Co. The company operates through three main businesses. Its Healthcare division develops and markets prescription medicines, including treatments in areas such as oncology, neurology and fertility.
Read More
- Five stocks we like better than Merck KGaA
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
